Benzimidazoles
Pantoprazole sodium salt hydrate
CAS: 718635-09-7 Molecular Formula: C16H14F2N3NaO4S Molecular Weight (g/mol): 405.35 MDL Number: MFCD08704580 InChI Key: YNWDKZIIWCEDEE-UHFFFAOYNA-N Synonym: pantoprazole sodium,pantoprazole sodium hydrate,pantozol hydrate,protonix hydrate,c16h14f2n3nao4s.h2o,sodium pantoprazole 1-hydrate,pantoprazole sodium hydrate hplc,5-difluoromethoxy-2-3,4-dimethoxypyridin-2-yl methanesulfinyl-1-sodio-1,3-benzodiazole hydrate,5-difluoromethoxy-2-3,4-dimethoxy-2-pyridinyl methyl sulfinyl-1h-benzimidazole sodium salt hydrate PubChem CID: 23684923 IUPAC Name: sodium;5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]benzimidazol-1-ide;hydrate SMILES: [Na+].COC1=C(OC)C(CS(=O)C2=NC3=CC(OC(F)F)=CC=C3[N-]2)=NC=C1
Rabeprazole Sodium Salt 98.0+%, TCI America™
CAS: 117976-90-6 Molecular Formula: C18H20N3NaO3S Molecular Weight (g/mol): 381.43 MDL Number: MFCD02092688 InChI Key: KRCQSTCYZUOBHN-UHFFFAOYNA-N PubChem CID: 14720269 ChEBI: CHEBI:8769 IUPAC Name: sodium 2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazol-1-ide SMILES: [Na+].COCCCOC1=CC=NC(CS(=O)C2=NC3=CC=CC=C3[N-]2)=C1C
Selleck Chemical LLC Omeprazole Sodium
Omeprazole Sodium is the sodium salt form of omeprazole which is a proton pump inhibitor and suppresses gastric acid secretion Omeprazole Sodium is a metabolism-dependent inhibitor (MDI) of CYP2C19
Medchemexpress LLC Omeprazole sodium | 95510-70-6 | 99.1% | 100 MG
Omeprazole sodium is a proton pump inhibitor (PPI) used for treating acid-related gastrointestinal disorders. It competitively inhibits CYP2C19 activity with a Ki of 2 to 6 μM. It also inhibits the growth of Gram-positive and Gram-negative bacteria and acts as a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
- Used for acid-related gastrointestinal disorders
- Competitively inhibits CYP2C19 activity with a Ki of 2 to 6 μM
- Inhibits the growth of Gram-positive and Gram-negative bacteria
- Potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)
- Used in the study of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome.
Medchemexpress LLC Omeprazole (sodium) | 95510-70-6 | 99.1% | C17H18N3NaO3S | 1 ML
Omeprazole sodium is a proton pump inhibitor (PPI) used to treat acid-related gastrointestinal disorders. It competitively inhibits CYP2C19 activity and also inhibits the growth of Gram-positive and Gram-negative bacteria. It acts as a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor.
- Proton pump inhibitor
- Treats acid-related gastrointestinal disorders
- Inhibits CYP2C19 activity
- Inhibits growth of Gram-positive and Gram-negative bacteria
- Potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor
- Purity: 99.1%
- Chemical formula: C17H18N3NaO3S
- Molecular Weight: 367.40
- Appearance: Solid
- Melting/freezing point: >165°C
Medchemexpress LLC (R)-Omeprazole sodium | 161796-77-6 | 98.1% | 50 MG
(R)-Omeprazole sodium is a gastric acid resistant compound that inhibits gastric acid secretion. Its metabolism in vivo is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. It exhibits reversible direct and metabolism-dependent inhibition of CYP2C19.
- Gastric acid resistant compound
- Inhibits gastric acid secretion
- Metabolized primarily by cytochrome P450 enzymes
- Interaction with mannitol may affect bioavailability
- Exhibits reversible direct and metabolism-dependent inhibition of CYP2C19
Medchemexpress LLC (R)-Omeprazole (sodium) | 161796-77-6 | 98.1% | 250 MG
(R)-Omeprazole sodium is a gastric acid resistant compound that inhibits gastric acid secretion. It is primarily metabolized in vivo by cytochrome P450 enzymes. Interactions with mannitol may affect its bioavailability in certain formulations.
- Inhibits gastric acid secretion
- Metabolized by cytochrome P450 enzymes
- Interacts with mannitol
- Reversibly inhibits CYP2C19 directly and metabolism-dependently
- For research use only
Medchemexpress LLC (R)-Omeprazole (sodium) | 161796-77-6 | 98.1% | 25 MG
(R)-Omeprazole sodium is a gastric acid resistant compound that inhibits gastric acid secretion. It is metabolized in vivo, primarily by cytochrome P450 enzymes, and its interaction with mannitol may affect its bioavailability in formulations. It exhibits reversible direct and metabolism-dependent inhibition of CYP2C19.
- Gastric acid resistant compound
- Inhibits gastric acid secretion
- Metabolized by cytochrome P450 enzymes
- Reversible direct and metabolism-dependent inhibition of CYP2C19
- For research use only
Medchemexpress LLC (R)-Omeprazole sodium | 161796-77-6 | 98.1% | 100 MG
(R)-Omeprazole sodium is a gastric acid resistant compound that inhibits gastric acid secretion. It is primarily metabolized by cytochrome P450 enzymes in vivo, and its interaction with mannitol may affect its bioavailability in formulations. This compound exhibits reversible direct and metabolism-dependent inhibition of CYP2C19. It is intended for research use only.
- Gastric acid resistant compound
- Inhibits gastric acid secretion
- Metabolism affected by cytochrome P450 enzymes
- May interact with mannitol affecting bioavailability
- Exhibits reversible direct and metabolism-dependent inhibition of CYP2C19
- For research use only
Sigma Aldrich Fine Chemicals Biosciences Pantoprazole sodium hydrate >=98% (HPLC) | 718635-09-7 | 50MG
Pantoprazole sodium hydrate >=98% (HPLC) | Purity: >=98% (HPLC) | 718635-09-7 | 50MG
Medchemexpress LLC (R)-omeprazole sodium | 161796-77-6 | 98.1% | C17H18N3NaO3S | 10MG
(R)-omeprazole sodium is the R-enantiomer of omeprazole supplied as the sodium salt. It is a gastric acid-resistant proton pump inhibitor used as a research reference standard to study gastric acid secretion and CYP2C19-mediated metabolism. The compound is provided with high chemical and enantiomeric purity for analytical and pharmacology studies.
- Molecular formula: C17H18N3NaO3S.
- Molecular weight: 367.4 g/mol.
- Purity: 98.1% (reported 98.07%).
- Enantiomeric excess: 99.84%.
- Function: reversible and metabolism-dependent inhibitor of CYP2C19.
- Intended use: reference standard and research compound for pharmacology and metabolism studies.
- Availability: includes small-scale 10 mg quantities suitable for analytical work.
Sigma Aldrich Fine Chemicals Biosciences Pantoprazole sodium hydrate >=98% (HPLC) | 718635-09-7 | 10MG
Pantoprazole sodium hydrate >=98% (HPLC) | Purity: >=98% (HPLC) | 718635-09-7 | 10MG
Medchemexpress LLC Omeprazole sodium | 95510-70-6 | MFCD07802816 | 99.10% | C17H18N3NaO3S | 500 MG
Omeprazole sodium is a proton pump inhibitor (PPI) used in the treatment of acid-related gastrointestinal disorders. It competitively inhibits CYP2C19 activity with a Ki of 2 to 6 μM. It also inhibits the growth of both Gram-positive and Gram-negative bacteria, and is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
- Proton pump inhibitor (PPI)
- Treats acid-related gastrointestinal disorders
- Competitively inhibits CYP2C19 activity with a Ki of 2 to 6 μM
- Inhibits growth of Gram-positive and Gram-negative bacteria
- Potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)
- Utilized in the study of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome